Profiling Mutations in Mexican Acute Myeloid Leukemia Pediatric Patients: Impact on Overall Survival.

Acute myeloid leukemia (AML) is the second most frequent leukemia in childhood. The gene participates in hematopoietic stem cell proliferation. mutations are recurrent in AML and influence prognosis. In Mexican pediatric AML patients, mutational profile, and their clinical impact have not been evaluated. This study aimed to identify the profile of mutations in pediatric patients with AML and to assess their possible influence on overall survival (OS) and other clinical features. Massive parallel target sequencing of was performed in 80 patients. mutations [internal tandem duplication (ITD) or tyrosine kinase domain (TKD)] were identified in 24% of them. OS was significantly lower in cases than in ( = 0.03). The average OS for was 1.2 vs. 2.2 years in . There were no significant differences in the children's sex, age, percentage of blasts in bone marrow aspirate, or white blood cell count in peripheral blood at diagnosis between both groups. No differences were identified stratifying by the mutational load (high > 0.4) or type of mutation. The negative effect of mutations was also observed in patients with acute promyelocytic leukemia (APL). mutational profile is described in Mexican pediatric AML patients for the first time. Mutated negatively impacts the outcome of AML patients, even considering the APL group. The clinical benefit from treatment with tyrosine kinase inhibitors in the pediatric patients needs to be assessed in clinical trials. testing may contribute to better risk stratification in our pediatric AML patients.